How it works:
Inhibits HIV reverse transcriptase, stopping viral replication
Indicated for treatment of HIV-1 in adults and adolescents
Approved for pre-exposure prophylaxis (PrEP)
Improved safety profile compared to older tenofovir formulations
Recommended for:
Patients with HIV-1 as part of antiretroviral therapy
Individuals at high risk of HIV infection (PrEP)
People with previous renal or bone-related side effects on TDF
Must be prescribed by an infectious disease specialist
For the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and adolescents aged 12 and older. Also indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1.
For the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and adolescents aged 12 and older. Also indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1.
Contraindications:
Hypersensitivity to any component
Age under 12 years
Renal impairment
Pregnancy and breastfeeding without medical consultation
Side effects:
Nausea
Headache
Fatigue
Diarrhoea
Liver enzyme elevation (rare)
Bone mineral density reduction (long-term use)